Baxter Recalls Vasopressin Injection Due to Manufacturing Deviations
Baxter Healthcare is voluntarily recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or structural defects are Severe; while no specific injuries are reported in the text, the Class II classification for a sterile IV drug with CGMP deviations warrants a Severe rating as it is not a Class I (Critical) but involves a potential for serious harm.
Plain-English summary
Baxter Healthcare Corporation is voluntarily recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container. The recall was initiated on August 6, 2026, and is classified as Class II by the FDA. The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations.
The affected product is distributed in the United States, Puerto Rico, and Chile. The specific lots subject to the recall are Lot # NC185448 (Expiration Date: 8/31/2027), Lot # NC192910 (Expiration Date: 4/30/2028), and Lot # NC195218 (Expiration Date: 6/30/2028). The product is a prescription-only, sterile intravenous injection.
Healthcare providers and patients should check their inventory and medication records for these specific lot numbers. If you have this product, do not use it and contact your healthcare provider or the manufacturer for instructions on how to return or dispose of the medication.
The recalled product
- Product
- VASOPRESSIN IN 0.9% SODIUM CHLORIDE (VASOPRESSIN IN 0.9% SODIUM CHLORIDE)
- Brand
- VASOPRESSIN IN 0.9% SODIUM CHLORIDE
- Manufacturer
- Baxter Healthcare Corporation
- Category
- Drug — Prescription Injection
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # NC185448
- Exp Date: 8/31/2027
- Lot # NC192910
- Exp Date: 4/30/2028
- Lot # NC195218
- Exp Date: 6/30/2028.
Distribution
Related recalls
Same brand · VASOPRESSIN IN 0.9% SODIUM CHLORIDE
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Same manufacturer · Baxter Healthcare Corporation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Same hazard · cgmp deviation
See all →- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls CARDENE IV Nicardipine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09